Certolizumab Pegol
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Certolizumab Pegol is used to treat psoriatic arthritis, rheumatoid arthritis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $284 million on Certolizumab Pegol across 39,000 claims for 6,670 beneficiaries.
Certolizumab Pegol is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $6072.51 to $6094.02 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$6072.51 – $6094.02
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
UCB, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Tumor Necrosis Factor Blocker class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing CERTOLIZUMAB PEGOL
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
CIMZIA 2X200 MG/ML SYRINGE KIT | $6094.0250 per EA | — |
CIMZIA 2X200 MG/ML(X3)START KT | $6072.5137 per EA | — |
Frequently Asked Questions
What is Certolizumab Pegol used to treat?
Certolizumab Pegol is used to treat psoriatic arthritis, rheumatoid arthritis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Certolizumab Pegol?
In 2024, Medicare Part D spent $284 million on Certolizumab Pegol across 39,000 claims for 6,670 beneficiaries.
How many Certolizumab Pegol products are on the market?
The Certolizumab Pegol drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Certolizumab Pegol?
NADAC reference prices for Certolizumab Pegol range from $6072.5137 to $6094.0250 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Certolizumab Pegol?
1 manufacturer lists Certolizumab Pegol in NADAC. Ranked by number of NDCs, the largest are UCB, Inc. (2).